Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions, such as atopic dermatitis (a type of eczema). Dupixent comes in a prefilled syringe or prefilled ...

Dupixent (dupilumab) is a prescription drug that’s used to treat certain inflammatory conditions. The drug comes as a solution for injection under the skin. How often you’ll receive a dose ...

TARRYTOWN, N.Y. and PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Commission (EC) has approved Dupixent ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

What is Dupixent for COPD? Dupixent (dupilumab) is an injectable therapy approved for adults with poorly controlled chronic obstructive pulmonary disease (COPD) and high counts in the bloodstream of a ...

FDA decision expected by April 18, 2025; if approved, Dupixent would be the first targeted therapy for CSU in a decade TARRYTOWN, N.Y. and PARIS, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Regeneron ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis Approval based on phase 3 data showing significantly more children aged one to 11 years ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi have announced that the European Commission has granted approval for Dupixent (dupilumab) to be utilized in the treatment of ...

Dupixent (dupilumab) – an IL-4 and IL-13 inhibitor – has dominated the market for biological therapies for atopic dermatitis since it was approved by the FDA in 2017.

Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up to ...

Revenues climbed 11% to $3.72 billion, driven by growth in Eylea HD sales, profits from blockbuster asthma drug Dupixent and oncology drug Libtayo. The top line beat the Zacks Consensus Estimate ...